KEY POINTS
- This retrospective single-center study included 199 patients with extensive-stage small-cell lung cancer receiving first-line platinum–etoposide chemotherapy plus a PD-1 or PD-L1 inhibitor between 2021 and 2025. 97 received consolidative thoracic RT after induction therapy and 102 received chemoimmunotherapy without thoracic consolidation.
- Consolidative RT was delivered after four to six induction chemotherapy cycles, before documented progression or second-line systemic treatment, commonly during maintenance immunotherapy. The preferred regimen was 50 Gy in 25 fractions, although dose and fractionation could be individualized; treatment generally targeted residual thoracic disease and initially involved nodal regions rather than elective uninvolved nodal stations.
- Median progression-free survival was 13.1 months with thoracic RT versus 7.6 months without RT (p<0.001), while reported median overall survival was 27.0 versus 15.5 months (p<0.001). The investigators also reported a strong survival association after propensity score matching, but this analysis included only 28 matched pairs.
- The treatment groups differed substantially in several major prognostic factors. Patients selected for thoracic RT were more likely to have achieved a complete or partial response after induction (72.2% vs 39.2%), far less likely to have residual thoracic disease ≥5 cm (7.2% vs 73.5%), and less likely to have brain metastases (27.8% vs 45.1%).
- Prophylactic cranial irradiation was also more common in the thoracic RT group (42.3% vs 18.6%). These differences suggest that consolidation was preferentially offered to patients with better disease response and prognosis, while calculating survival from the beginning of systemic treatment creates additional potential for immortal-time bias, because patients had to remain eligible long enough to receive subsequent RT.
- An internal reporting inconsistency further complicates interpretation: although median OS substantially favored thoracic RT, the published two-year OS percentages were 36.08% with RT versus 37.25% without RT. These figures do not align readily with the reported median survival and overall separation of the Kaplan–Meier curves, and should be clarified before the study's survival effect estimates are used clinically.
- Severe toxicity was not statistically different between groups. Grade 3–4 pneumonitis occurred in 4.1% with thoracic RT versus 5.9% without, and grade 3–4 esophagitis in 6.2% versus 2.0%, while grade 1–2 dermatitis (21.6% vs 3.9%) and gastrointestinal toxicity (41.2% vs 21.6%) were more frequent with consolidation.
CLINICAL TAKEAWAY
Thoracic consolidation after first-line chemoimmunotherapy remains a potentially useful approach for selected patients with extensive-stage SCLC and controlled residual thoracic disease. Although this retrospective study reported substantially longer survival with RT and no clear increase in severe toxicity, pronounced baseline imbalances, possible immortal-time bias and inconsistent reported survival estimates prevent reliable attribution of the benefit to thoracic irradiation; prospective randomized evidence is needed.